Study Examines Efficacy of Zavzpret Nasal Spray Treatment in Black and African-American Patients with Migraine

For Black and African-American people with migraine, treatment with Zavzpret (zavegepant; Pfizer, New York, NY) nasal spray resulted in clinical efficacy outcomes similar to those found in the overall population. Results of pooled subgroup analyses based on data from 2 studies were presented at the 66th Annual Scientific Meeting of the American Headache Society (AHS).

The analyzed data were derived from a phase 2/3 (NCT03872453) and a phase 3 (NCT04571060) double-blind, placebo-controlled study, both assessing the safety and efficacy of Zavzpret as a treatment for moderate to severe migraine. The pooled subgroup analyses evaluated co-primary endpoints of freedom from pain and freedom from most bothersome symptom (MBS) measured 2 hours after administration of placebo or Zavzpret at 10 mg intranasally. Researchers compared treatment groups within the overall population (N=2061) and the subgroup of Black and African-American adults (n=298). There were 157 Black and African-American participants who received Zavzpret and 141 who received placebo.

In terms of freedom from pain:

• Response rates were 34.4% for Black and AfricanAmerican participants who received Zavzpret and 17.0% for those receiving placebo (P=.0004).
• In the overall population, response rates were 23.2% for those receiving Zavzpret and 15.1% for those receiving placebo (P=.0001).

In terms of freedom from MBS:

• In the subgroup of Black and AfricanAmerican participants, response rates were 42.7% for those receiving Zavzpret and 34.0% for those receiving placebo (P=.1287).
• Response rates were 40.5% for participants in the overall population who received Zavzpret and 32.1% for those receiving placebo (P=.0001).

This study was conducted with funding from Pfizer.